ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1701

Long Term Outcome of Total Hip Replacement in Patients with Ankylosing Spondylitis

Ana Lizarraga1, Natalia Zamora1, Graciela Betancur1, Luis Alejandro Cayetti2, Emilce Schneeberger2, Maria Celeste Orozco3, Fernando Andres Sommerfleck4 and Gustavo Citera3, 1Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 2Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 3Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 4Rheumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Ankylosing spondylitis (AS)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Comorbidities and Treatment Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Total hip replacement (THR) surgery is a reliable therapeutic intervention for patients with severe hip involvement. The aim of our study was to determine the long term outcome and associated risk factors of THR in patients with Ankylosing Spondylitis (AS).

Methods: Patients ≥ 18 years with AxSpA diagnosis according to ASAS or NY criteria of ESPAXIA cohort were included. Demographic data, disease duration, comorbidities and current treatment were collected. Pain, patient global assessment (VAS), disease activity (BASDAI), functional capacity (BASFI), enthesitis (MASES), axial mobility (BASMI) and radiological damage (mSASSS) were assessed. THR data included: date of each total hip arthroplasty (right, left), surgery complications and revision. Actual hip pain by VAS and Steimbroker functional class (FC I-IV). Patients were asked to determine the level of pain previous to the surgery (VAS). Hips functional capacity was evaluated by Merle d´Aubigné and Postel method. Pelvis x rays were taken to determine: presence of periprosthesic osteolysis of the femoral and acetabular components, fracture, luxation and heterotopic ossification (HO) according to Brooker´s classification. Statistical analysis: T test, Mann Whitney, Chi2and Fisher test. Multiple logistic regression analysis to explore risk factors associated to THR. 

Results: 190 patients were evaluated and 25 (13,15%) underwent THR. 16 patients were included in the analysis (2 died and 7 lost follow-up). Nine (56,2%) had bilateral THR. Fifteen (93,8%) were male, median age of 45 years (IQR 35-44), median disease duration 28,5 years (IQR 18-35,2). 11 (68,8%) were HLA-B27positive . The median time of THR′s evolution was 12,5 years (IQR 8.7-16.7). 25 prosthesis were evaluated (14 right y 11 left). 48% were cemented and 54% were non cemented. 3 (12%) prosthesis had surgery complications, 3 (12%) had revision surgery. A relief of pain was observed after THR surgery median pain (VAS) previous surgery 10 cm (IQR 9.7-10) vs 0 cm (IQR 0-1.2). There was also improvement after the surgery in FC: 6 (24%) class II, 16 (64%) class III y 3 (12%) class IV and at the moment of evaluation 15 (60%) class II y 10 (40%) class III. Merle d`Aubigné and Postel method median value 15,2 (IQR 13,5-17). We evaluated 22 THR x rays. 11 (50%) prosthesis had acetabular osteolysis, 3 (13,6%) subluxation and 1 peri-prosthesis fracture. 15/17 hips (88,2 %) had femoral osteolysis. 15 had heterotopic ossification, (4 grade I, 4 II, 6 III y 1 IV ). THR was associated with longer disease duration (27,1 ± 10,6 vs 19,6 ± 13,4 years, p= 0,03), younger age at the beginning of symptoms (17,4 ±7,6 vs 26,2 ±11,9 years, p= 0,0001), minor MASES (0,6 ±1,2 vs 1,6 ±2,3 p= 0,007) and more frequency of biologic treatment (50% vs 23,6%, p=0,03). In the multivariate analysis, the only variable independently associated with THR was younger age at the beginning of symptoms [β 0,91 (IC95% 0,85-0,97) p=0,001]. 

Conclusion: A substantial relief in pain and improvement of functional capacity were seen in AS patients who underwent THR . Younger age at disease onset was the only predictor associated to THR.


Disclosure: A. Lizarraga, None; N. Zamora, None; G. Betancur, None; L. A. Cayetti, None; E. Schneeberger, None; M. C. Orozco, None; F. A. Sommerfleck, None; G. Citera, None.

To cite this abstract in AMA style:

Lizarraga A, Zamora N, Betancur G, Cayetti LA, Schneeberger E, Orozco MC, Sommerfleck FA, Citera G. Long Term Outcome of Total Hip Replacement in Patients with Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/long-term-outcome-of-total-hip-replacement-in-patients-with-ankylosing-spondylitis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-outcome-of-total-hip-replacement-in-patients-with-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology